Christine L. Phillips, MD

Impact of Current Manufacturing on Kymriah Real-World Effectiveness and Functional Persistence in Acute Lymphoblastic Leukemia (ALL) (KareALL): A Retrospective Study of Tisagenlecleucel (tisa-cel)-Treated Pediatric and Young Adult Patients (pts) with ALL. Rouce, R; Dolan, JG; Phillips, CL; Qayed, M; Pulsipher, MA; Vernau, LM; Galletta, TJ; Votaw, S; Llaurador Caraballo, G; Yang, H; Tesfaye, M; Lee, S; O'Sullivan, E; Grupp, SA. Blood. 2024; 144:7724.

Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients. LeBlanc, FR; Breese, EH; Burns, KC; Chang, EK; Jones, LQ M; Lee, L; Mizukawa, B; Norris, RE; O'Brien, MM; Phillips, CL; Perentesis, JP; Rubinstein, J; Pommert, L. British Journal of Haematology. 2024; 205:1055-1066.

Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns. Barsan, V; Li, Y; Prabhu, S; Baggott, C; Nguyen, K; Pacenta, H; Phillips, CL; Rossoff, J; Stefanski, H; Talano, J; Curran, KJ; Mackall, CL; Laetsch, TW; Schultz, LM. EClinicalMedicine. 2023; 65:102268.

Mediport use as an acceptable standard for CAR T cell infusion. Eylon, M; Prabhu, S; John, S; King, MJ M; Bhatt, D; Curran, KJ; Erickson, C; Karras, NA; Phillips, CL; Satwani, P; Fabrizio, VA; Baggott, C; Laetsch, TW; Schultz, LM. Frontiers in Immunology. 2023; 14:1239132.

Male pediatric, adolescent, and young adult reproductive survivorship. Burns, K; Phillips, C; Brannigan, R; Franklin, A; Howell, J; Schmidt, D; Sopfe, J; Appiah, LC; Anazodo, A. Pediatric Blood and Cancer. 2023; 70 Suppl 5:e28823.

Post CAR T-cell therapy outcomes and management in HSCT-naive patients: a single-center experience. Phillips, CL; Krupski, C; Khoury, R; Dandoy, CE; Nelson, AS; Galletta, TJ; Faulhaber, A; Davies, SM; Rubinstein, JD. 2023; 2:1151744.

Durable remissions achieved with reinfusion of CD19-directed CAR-T despite failure to induce or maintain B-cell aplasia and single-center experience with reinfusion of tisagenlecleucel. Galletta, TJ; Rubinstein, JD; Krupski, C; Nelson, AS; Khoury, R; Dandoy, CE; Davies, SM; Phillips, CL. Pediatric Blood and Cancer. 2023; 70:e30271.

The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL. Rubinstein, JD; Breese, EH; Krupski, MC; O'Brien, MM; Dandoy, CE; Mizukawa, B; Khoury, R; Norris, RE; Davies, SM; Phillips, CL. Transplantation and Cellular Therapy. 2023; 29:311.e1-311.e7.

Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium. Stefanski, HE; Eaton, A; Baggott, C; Rossoff, J; Verneris, MR; Prabhu, S; Pacenta, HL; Phillips, CL; Talano, J; Moskop, A; Curran, KJ; Mackall, CL; Laetsch, TW; Schultz, LM. Blood Advances. 2023; 7:541-548.

Tocilizumab for Treatment of Children and Young Adults With Severe Acute COVID-19: Experience at a Quaternary-care Children's Hospital. Teoh, Z; Danziger-Isakov, L; Courter, JD; Frenck, RW; Grimley, MS; Marsh, RA; Paulsen, GC; Phillips, CL; Spearman, P; Chima, RS; Schulert, GS. The Pediatric Infectious Disease Journal. 2023; 42:119-121.